{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:28:53Z","timestamp":1760059733788,"version":"build-2065373602"},"reference-count":62,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T00:00:00Z","timestamp":1751587200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The Research of Khon Kaen University, Thailand"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Life"],"abstract":"<jats:p>Background: Currently, no information exists on the clinical course of anti-topoisomerase I antibody (ATA)-positive limited cutaneous systemic sclerosis (lcSSc). We aimed to evaluate the incidence of and time to the development of interstitial lung disease (ILD), pulmonary hypertension (PHT), scleroderma renal crisis (SRC), and maximal modified Rodnan skin score (max-mRSS) in patients with lcSSc and dcSSc, with and without ATA. Methods: This cohort study included 522 patients with systemic sclerosis (SSc). The incidence of and time to the development of ILD, PHT, SRC, and max-mRSS were assessed. Results: ATA-positive dcSSc (dcSSc-posATA) was the most common presentation among Thai patients (321 cases; 61.5%). The median time to the development of ILD was shorter than that in lcSSc-posATA, comparable to that in dcSSc-posATA (1.0 vs. 1.8 years, p = 0.21), and shorter than that in ATA-negative dcSSc (dcSSc-negATA) (1.0 vs. 4.8 years, p = 0.001). The time to max-mRSS in lcSSc-posATA was comparable to that in dcSSc-posATA (p = 0.17) but shorter than that in dcSSc-negATA (p &lt; 0.001). Conclusions: Patients with lcSSc-posATA had a similar risk of ILD development and time to reach max-mRSS as those with dcSSc, regardless of the presence of ATA, but had earlier ILD development and max-mRSS compared to those with dcSSc-negATA. Their prognosis appeared to be better than that of dcSSc-posATA.<\/jats:p>","DOI":"10.3390\/life15071067","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T03:47:26Z","timestamp":1751600846000},"page":"1067","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Redefining Systemic Sclerosis Classification: Anti-Topoisomerase Antibody as a Superior Predictor of Interstitial Lung Disease and Skin Progression Compared to Limited Cutaneous Systemic Sclerosis Subset"],"prefix":"10.3390","volume":"15","author":[{"given":"Chana","family":"Chaovanitkul","sequence":"first","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8332-5447","authenticated-orcid":false,"given":"Tippawan","family":"Onchan","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-7746-8458","authenticated-orcid":false,"given":"Patnarin","family":"Pongkulkiat","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7091-0259","authenticated-orcid":false,"given":"Ajanee","family":"Mahakkanukrauh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siraphop","family":"Suwannaroj","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1964-4389","authenticated-orcid":false,"given":"Chingching","family":"Foocharoen","sequence":"additional","affiliation":[{"name":"Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.semarthrit.2008.06.002","article-title":"Determinants of Morbidity and Mortality of Systemic Sclerosis in Canada","volume":"39","author":"Pope","year":"2010","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_2","first-page":"202","article-title":"Scleroderma (Systemic Sclerosis): Classification, Subsets and Pathogenesis","volume":"15","author":"LeRoy","year":"1988","journal-title":"J. Rheumatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.1780370111","article-title":"Clinical and Prognostic Associations Based on Serum Antinuclear Antibodies in Japanese Patients with Systemic Sclerosis","volume":"37","author":"Kuwana","year":"1994","journal-title":"Arthritis Rheum."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1272\/jnms.84.56","article-title":"Circulating Anti-Nuclear Antibodies in Systemic Sclerosis: Utility in Diagnosis and Disease Subsetting","volume":"84","author":"Kuwana","year":"2017","journal-title":"J. Nippon. Med. Sch."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology\/European League against Rheumatism Collaborative Initiative","volume":"65","author":"Khanna","year":"2013","journal-title":"Arthritis Rheum."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1111\/1756-185X.12492","article-title":"Scleroderma Research Group Clinical Differences between Thai Systemic Sclerosis Patients with Positive versus Negative Anti-Topoisomerase I","volume":"19","author":"Foocharoen","year":"2016","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in Systemic Sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1756-185X.2011.01688.x","article-title":"South Australian Scleroderma Register: Autoantibodies as Predictive Biomarkers of Phenotype and Outcome","volume":"15","author":"Graf","year":"2012","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"272","DOI":"10.3109\/s10165-011-0515-7","article-title":"Clinical Features of 405 Japanese Patients with Systemic Sclerosis","volume":"22","author":"Hashimoto","year":"2012","journal-title":"Mod. Rheumatol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s10067-012-2145-7","article-title":"Clinical and Serological Features of Systemic Sclerosis in a Chinese Cohort","volume":"32","author":"Wang","year":"2013","journal-title":"Clin. Rheumatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1007\/s00296-013-2668-5","article-title":"Systemic Sclerosis: Demographic, Clinical and Serological Features in 100 Iranian Patients","volume":"33","author":"Poormoghim","year":"2013","journal-title":"Rheumatol. Int."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/1756-185X.13060","article-title":"Relevance of Clinical and Autoantibody Profiles in Systemic Sclerosis among Thais","volume":"20","author":"Foocharoen","year":"2017","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1111\/1756-185X.13859","article-title":"Clinical Characteristics and Outcomes of 566 Thais with Systemic Sclerosis: A Cohort Study","volume":"23","author":"Foocharoen","year":"2020","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.autrev.2012.07.005","article-title":"Diagnostic Accuracy and Predictive Value of Extended Autoantibody Profile in Systemic Sclerosis","volume":"12","author":"Villalta","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Kayser, C., and Fritzler, M.J. (2015). Autoantibodies in Systemic Sclerosis: Unanswered Questions. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00167"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12016-012-8331-1","article-title":"Impact of Hallmark Autoantibody Reactivity on Early Diagnosis in Scleroderma","volume":"43","author":"Moinzadeh","year":"2012","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.semarthrit.2015.04.009","article-title":"Canadian Scleroderma Research Group (CSRG) Thinking Outside the Box-The Associations with Cutaneous Involvement and Autoantibody Status in Systemic Sclerosis Are Not Always What We Expect","volume":"45","author":"Srivastava","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s12016-018-8718-8","article-title":"Antinuclear Antibodies in Systemic Sclerosis: An Update","volume":"58","author":"Stochmal","year":"2020","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3985","DOI":"10.1002\/art.20676","article-title":"Digital Ulcers in Systemic Sclerosis: Prevention by Treatment with Bosentan, an Oral Endothelin Receptor Antagonist","volume":"50","author":"Korn","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1007\/s40674-016-0052-9","article-title":"Hand Impairment in Systemic Sclerosis: Various Manifestations and Currently Available Treatment","volume":"2","author":"Young","year":"2016","journal-title":"Curr. Treatm Opt. Rheumatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1801913","DOI":"10.1183\/13993003.01913-2018","article-title":"Haemodynamic Definitions and Updated Clinical Classification of Pulmonary Hypertension","volume":"53","author":"Simonneau","year":"2019","journal-title":"Eur. Respir. J."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e279","DOI":"10.1016\/j.lpm.2014.03.029","article-title":"Gastrointestinal Involvement in Systemic Sclerosis","volume":"43","author":"Savarino","year":"2014","journal-title":"Presse Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.mcna.2014.01.012","article-title":"Involuntary Weight Loss","volume":"98","author":"Wong","year":"2014","journal-title":"Med. Clin. North. Am."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/1756-185X.12322","article-title":"Clinical and Autoantibody Profile in Systemic Sclerosis: Baseline Characteristics from a West Malaysian Cohort","volume":"18","author":"Sujau","year":"2015","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1445-5994.2001.00048.x","article-title":"Scleroderma in South Australia: Epidemiological Observations of Possible Pathogenic Significance","volume":"31","author":"Jones","year":"2001","journal-title":"Intern. Med. J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1445-5994.1999.tb01587.x","article-title":"Systemic Sclerosis Prevalence and Mortality in Sydney 1974-88","volume":"29","author":"Englert","year":"1999","journal-title":"Aust. N. Z. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/BF00371817","article-title":"Epidemiological Study of Patients with Systemic Sclerosis in Tokyo","volume":"283","author":"Tamaki","year":"1991","journal-title":"Arch. Dermatol. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/ard.53.8.502","article-title":"Systemic Sclerosis in Iceland. A Nationwide Epidemiological Study","volume":"53","author":"Geirsson","year":"1994","journal-title":"Ann. Rheum. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-200203000-00004","article-title":"Systemic Sclerosis: Demographic, Clinical, and Serologic Features and Survival in 1,012 Italian Patients","volume":"81","author":"Ferri","year":"2002","journal-title":"Medicine"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1136\/ard.2005.036038","article-title":"Systemic Sclerosis in Europe: First Report from the EULAR Scleroderma Trials And Research (EUSTAR) Group Database","volume":"64","author":"Tyndall","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"ref_31","first-page":"S-10-14","article-title":"Sex and Time to Diagnosis in Systemic Sclerosis: An Updated Analysis of 1,129 Patients from the Canadian Scleroderma Research Group Registry","volume":"32","author":"Delisle","year":"2014","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1053\/sarh.2001.20268","article-title":"GENISOS Study Group Systemic Sclerosis in 3 US Ethnic Groups: A Comparison of Clinical, Sociodemographic, Serologic, and Immunogenetic Determinants","volume":"30","author":"Reveille","year":"2001","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1002\/art.22747","article-title":"Clinical Subsets, Skin Thickness Progression Rate, and Serum Antibody Levels in Systemic Sclerosis Patients with Anti-Topoisomerase I Antibody","volume":"56","author":"Perera","year":"2007","journal-title":"Arthritis Rheum."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-L\u00f3pez, M., and Carreira, P.E. (2023). The Impact of Progressive Pulmonary Fibrosis in Systemic Sclerosis-Associated Interstitial Lung Disease. J. Clin. Med., 12.","DOI":"10.3390\/jcm12206680"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41584-023-01044-x","article-title":"Systemic Sclerosis Interstitial Lung Disease: Unmet Needs and Potential Solutions","volume":"20","author":"Liakouli","year":"2024","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/2397198320903867","article-title":"Pathogenesis of Systemic Sclerosis Associated Interstitial Lung Disease","volume":"5","author":"Nihtyanova","year":"2020","journal-title":"J. Scleroderma Relat. Disord."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/qjmed\/hcm052","article-title":"Scleroderma Renal Crisis: Patient Characteristics and Long-Term Outcomes","volume":"100","author":"Penn","year":"2007","journal-title":"QJM"},{"key":"ref_38","first-page":"29","article-title":"Prevalence and Clinical Features of Acute Kidney Injury in Thai Systemic Sclerosis Patients","volume":"2","author":"Foocharoen","year":"2016","journal-title":"KKU Med. J."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1136\/ard.2006.066985","article-title":"Mortality and Risk Factors of Scleroderma Renal Crisis: A French Retrospective Study of 50 Patients","volume":"67","author":"Teixeira","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1136\/ard.2009.127621","article-title":"Skin Thickness Progression Rate: A Predictor of Mortality and Early Internal Organ Involvement in Diffuse Scleroderma","volume":"70","author":"Domsic","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3899\/jrheum.091048","article-title":"Association of RNA Polymerase III Antibodies with Scleroderma Renal Crisis","volume":"37","author":"Nguyen","year":"2010","journal-title":"J. Rheumatol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1093\/mr\/roac028","article-title":"Management Review of Scleroderma Renal Crisis: An Update with Practical Pointers","volume":"33","author":"Foocharoen","year":"2023","journal-title":"Mod. Rheumatol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/S0889-857X(03)00016-4","article-title":"Scleroderma Renal Crisis","volume":"29","author":"Steen","year":"2003","journal-title":"Rheum. Dis. Clin. North. Am."},{"key":"ref_44","first-page":"722","article-title":"Scleroderma Renal Crisis as an Early Presentation of Systemic Sclerosis","volume":"11","author":"Dolnikov","year":"2020","journal-title":"Isr. Med. Assoc. J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3899\/jrheum.121380","article-title":"The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review","volume":"40","author":"Muangchan","year":"2013","journal-title":"J. Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1136\/annrheumdis-2017-211448","article-title":"Mapping and Predicting Mortality from Systemic Sclerosis","volume":"76","author":"Elhai","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in Causes of Death in Systemic Sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann. Rheum. Dis."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2014.05.010","article-title":"Mortality and Survival in Systemic Sclerosis: Systematic Review and Meta-Analysis","volume":"44","author":"Royo","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1164\/rccm.202306-1113ST","article-title":"Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: Evidence-Based Recommendations. An Official American Thoracic Society Clinical Practice Guideline","volume":"209","author":"Raghu","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1093\/rheumatology\/kev096","article-title":"Asymptomatic Cardiac Involvement in Thai Systemic Sclerosis: Prevalence and Clinical Correlations with Non-Cardiac Manifestations (Preliminary Report)","volume":"54","author":"Foocharoen","year":"2015","journal-title":"Rheumatology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.amjms.2021.05.027","article-title":"Clinical Outcomes of Asymptomatic Cardiac Involvement in Systemic Sclerosis Patients After a 2-Year Follow-Up (Extended Study)","volume":"362","author":"Pussadhamma","year":"2021","journal-title":"Am. J. Med. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1111\/1756-185X.13727","article-title":"Clinical and Laboratory Predictions of Myocardial Inflammation as Detected by Cardiac Magnetic Resonance Imaging in Patients with Systemic Sclerosis: A Pilot Study","volume":"22","author":"Tipparot","year":"2019","journal-title":"Int. J. Rheum. Dis."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1515\/rir-2024-0015","article-title":"Outcomes of Myocarditis in Systemic Sclerosis: A 3-Year Follow-Up","volume":"5","author":"Mahakkanukrauh","year":"2024","journal-title":"Rheumatol. Immunol. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"8884442","DOI":"10.1155\/2020\/8884442","article-title":"Clinical Outcomes of Myocarditis after Moderate-Dose Steroid Therapy in Systemic Sclerosis: A Pilot Study","volume":"2020","author":"Pussadhamma","year":"2020","journal-title":"Int. J. Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1515\/rir-2024-0014","article-title":"Clinical Courses and Predictors of Left Ventricular Systolic Dysfunction in Systemic Sclerosis: A Cohort Study","volume":"5","author":"Werakiat","year":"2024","journal-title":"Rheumatol. Immunol. Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in Systemic Sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.24409","article-title":"Anti-U3 RNP Autoantibodies in Systemic Sclerosis","volume":"60","author":"Aggarwal","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/40.10.1157","article-title":"Anti-Fibrillarin Antibodies in Systemic Sclerosis","volume":"40","author":"Tormey","year":"2001","journal-title":"Rheumatology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/art.24586","article-title":"Anti-U11\/U12 RNP Antibodies in Systemic Sclerosis: A New Serologic Marker Associated with Pulmonary Fibrosis","volume":"61","author":"Fertig","year":"2009","journal-title":"Arthritis Rheum."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/art.10914","article-title":"Autoantibodies against B23, a Nucleolar Phosphoprotein, Occur in Scleroderma and Are Associated with Pulmonary Hypertension","volume":"49","author":"Ulanet","year":"2003","journal-title":"Arthritis Rheum."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1136\/ard.2007.073981","article-title":"Prevalence and Clinical Associations of Anti-Ku Antibodies in Patients with Systemic Sclerosis: A European EUSTAR-Initiated Multi-Centre Case-Control Study","volume":"67","author":"Rozman","year":"2008","journal-title":"Ann. Rheum. Dis."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Mulalin, K., Mahakkanukrauh, A., Suwannaroj, S., Pongkulkiat, P., Onchan, T., Kasa, S., and Foocharoen, C. (2024). Levels of Anti-Topoisomerase I Antibody Correlated with Short Onset of Cardiopulmonary Involvement in Thai Systemic Sclerosis Patients. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-61159-3"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/7\/1067\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:04:17Z","timestamp":1760033057000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/7\/1067"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,4]]},"references-count":62,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["life15071067"],"URL":"https:\/\/doi.org\/10.3390\/life15071067","relation":{},"ISSN":["2075-1729"],"issn-type":[{"type":"electronic","value":"2075-1729"}],"subject":[],"published":{"date-parts":[[2025,7,4]]}}}